-
Ruxolitinib phosphate: Reliable Cell Assays
2026-09-04
A scenario-driven guide to using Ruxolitinib phosphate (SKU A3781) for reproducible viability, proliferation, and cytotoxicity experiments. It connects JAK/STAT pathway biology with practical formulation, controls, interpretation, and vendor-selection decisions.
-
HyperScript First-Strand cDNA Synthesis Kit Guide
2026-09-04
Build sensitive, reproducible cDNA workflows for low-abundance transcripts, structured RNA templates, and long amplicons. This guide shows how to choose primers, tune reverse transcription, and troubleshoot downstream PCR amplification and qPCR reaction variability with K1072.
-
hCG, EZH2, and CXCL10 in Decidual Immune Control
2026-09-03
Silasi and colleagues showed that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal-cell models through EZH2-dependent deposition of H3K27me3 at the CXCL10 promoter. The study links placental endocrine signaling to chromatin remodeling and CD8 T-cell recruitment, providing a mechanistic framework for understanding immune regulation at the maternal–fetal interface.
-
Prednisone Workflows for Apoptosis and Immune Assays
2026-09-03
Prednisone provides a practical model for connecting lymphocyte G1 arrest, IL-2 pathway suppression, and apoptosis in controlled immune-cell assays. This workflow also adds matrix-aware sampling and metabolomics-inspired quality controls, helping researchers distinguish pharmacology from formulation or handling artifacts.
-
SIRT1/2 Inhibitor IV (cambinol) Guide
2026-09-02
A scenario-driven guide to using SIRT1/2 Inhibitor IV (cambinol), SKU B6063, in cell viability, apoptosis, acetylation, metabolic, and tumor-model workflows. It emphasizes dose interpretation, vehicle controls, orthogonal readouts, and evidence-based product selection.
-
Diminazene Aceturate Research Workflows
2026-09-02
Diminazene Aceturate supports two distinct research paths: trypanosome parasite screening and mechanism-focused ACE2 activation studies. This workflow-led guide covers formulation, controls, mitochondrial readouts, and troubleshooting while keeping preclinical findings separate from clinical claims.
-
TAK-715: A Practical p38 MAPK Inhibitor Workflow
2026-09-01
TAK-715 combines nanomolar p38α inhibition with a useful experimental profile for cytokine, inflammation, and rheumatoid arthritis research. This workflow explains how to prepare, dose, validate, and troubleshoot the compound while separating established product data from emerging dual-action mechanistic hypotheses.
-
Pioglitazone: PPARγ Agonist Research Guide
2026-09-01
Pioglitazone is a selective PPARγ agonist for studying insulin sensitivity, beta-cell protection, macrophage polarization, and inflammatory signaling. Evidence from receptor assays and a DSS-induced intestinal inflammation model connects PPARγ activation with metabolic regulation and STAT-1/STAT-6 pathway changes.
-
Standardized Whole-Blood Stimulation for Immunometabolism
2026-08-31
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with targeted metabolic interventions and cytokine measurement. The workflow offers a reproducible way to study how metabolic pathways selectively shape human immune responses while clarifying the controls needed for cohort-scale and translational studies.
-
Salinomycin Workflows for HCC Research
2026-08-31
Build a more interpretable Salinomycin workflow by connecting ion transport, Wnt/β-catenin signaling, calcium flux, and apoptosis rather than relying on viability alone. This practical framework differentiates formulation, timing, and mechanism-testing decisions for hepatocellular carcinoma research.
-
Adiponectin, TLR4, and Cognitive Deficits After Surgery
2026-08-30
This reference study identifies suppression of the TLR4/MyD88/NF-κB axis as a potential mechanism by which adiponectin protects aged rats from splenectomy-associated cognitive impairment. Pharmacological inhibition with TAK-242 and pathway reversal with LPS strengthen the proposed link between neuroinflammation, oxidative stress, and postoperative cognitive dysfunction, while also defining important limits for translation.
-
FCCP: Mitochondrial Uncoupling Workflows
2026-08-29
Use FCCP to connect mitochondrial respiration with ATP loss, HIF signaling, and organelle quality-control phenotypes. This practical guide translates the MARCH5 pre-peroxisome study into dose-controlled workflows for mitochondrial biology research, metabolic regulation studies, and cancer models.
-
Maternal IL-17A and Neonatal GBS Risk
2026-08-28
A prospective mother–newborn study in Morocco links reduced maternal IL-17A, IL-1β, and IL-4 responses with invasive Group B Streptococcus disease in newborns. By combining clinical cytokine profiling with ex vivo TLR1/2 and TLR4 stimulation, the study positions maternal IL-17A as a candidate risk-stratification biomarker rather than a marker of colonization alone.
-
HAUS1, Immune Contexture, and HCC Prognosis
2026-08-28
The reference study integrates public cancer datasets, immune-infiltration analyses, survival modeling, and siRNA experiments to define HAUS1 as a clinically relevant factor in hepatocellular carcinoma (HCC). Its findings connect elevated HAUS1 with adverse disease features, tumor-cell proliferation, and an immunologically relevant tumor environment, while also identifying limitations that require prospective and mechanistic validation.
-
Aprotinin in Protease-Controlled RNA Workflows
2026-08-27
Aprotinin adds a testable serine-protease control layer to nuclei, plasma, and inflammation workflows without changing the core readout. This article translates the rRNA-depleted GRO-seq strategy into practical assay design while separating established evidence from research-use-only optimization.